Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 5,128 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1081
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more

Conditions: Hoarding Disorder
Interventions: Group Cognitive Behavioral Therapy, Peer Facilitated Support Group; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 45
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more

Conditions: Stress Disorders, Posttraumatic
Interventions: Hydrocortisone, D-Cycloserine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteer, Older Adults (65-85 Years)
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Toxoplasmosis, Cerebral, HIV Infections
Interventions: Pyrimethamine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Renal Dysfunction, Hypertension
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson Disease
Interventions: BIIB122, BIIB122-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: San Francisco, California • Aurora, Colorado • Englewood, Colorado + 8 more

Conditions: Malignant Mesothelioma
Interventions: capecitabine; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more

Conditions: Ureteral Stone
Interventions: Ureteroscopy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Non Alcoholic Steatohepatitis (NASH)
Interventions: Obeticholic Acid, Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 175
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 45
States / cities: La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more

Conditions: Acute Myeloid Leukemia
Interventions: ASTX660, ASTX727; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 11 more

Conditions: Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Ficlatuzumab, Cytarabine; Drug
Lead sponsor: C. Babis Andreadis; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) sustained release tablets, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: levofloxacin; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 78
States / cities: Little Rock, Arkansas • Downey, California • Duarte, California + 65 more

Conditions: Type 1 Diabetes Mellitus
Interventions: DHA Treatment, Placebo for DHA; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 5 Months
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 6 more

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Renal Cell Carcinoma
Interventions: Tivozanib, Nivolumab; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Duarte, California • Irvine, California • La Jolla, California + 31 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Moderate Intensity Exercise Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections, Pregnancy
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 69
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 40 more

Conditions: HIV, Cardiovascular Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Priscilla Hsue, MD; Other
Eligibility: 40 Years to 59 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Phoenix, Arizona • Fresno, California • Orange, California + 38 more

Search by objective public record fields.

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Comparison of Treatment for Hoarding Disorder

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Veteran Stress and Learning Study

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Capecitabine in Treating Patients With Malignant Mesothelioma

UPURS Trial for Patient-centered Management of Symptomatic Obstructing Stones

Transforming Research and Clinical Knowledge in Geriatric Traumatic Brain Injury (TRACK-GERI)

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Nutritional Intervention to Prevent Diabetes

Dyspnea in Patients With Pulmonary Fibrosis

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Phase 3 Extension Study of Dexpramipexole in ALS